Search research articles
Contact Us
Filters
Showing results (141-150 of 223) with videos related to
Page
of 23
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
Pietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Blood
|
April 30, 2014
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
Uri Rozovski, Ji Yuan Wu, David M Harris, et al.
Molecular Cancer
|
June 4, 2013
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
Uri Rozovski, George A Calin, Tetsuro Setoyama, et al.
Leukemia
|
February 12, 2022
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures
Alicia M Vaca, Nikolaos Ioannou, Mariela Sivina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure
Uri Rozovski, Ohad Benjamini, Preetesh Jain, et al.
Leukemia & Lymphoma
|
January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Jan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Cancer Immunology Research
|
July 19, 2019
SLAMF6 as a Regulator of Exhausted CD8<sup>+</sup> T Cells in Cancer
Burcu Yigit, Ninghai Wang, Elisa Ten Hacken, et al.
Page
of 23
Search research articles
Search
Showing results (141-150 of 223) with videos related to
Sort By:
Page
of 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 12, 2014
CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia
Pietro Bulian, Tait D Shanafelt, Chris Fegan, et al.
Blood
|
April 30, 2014
Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells
Uri Rozovski, Ji Yuan Wu, David M Harris, et al.
Molecular Cancer
|
June 4, 2013
Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells
Uri Rozovski, George A Calin, Tetsuro Setoyama, et al.
Leukemia
|
February 12, 2022
Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures
Alicia M Vaca, Nikolaos Ioannou, Mariela Sivina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure
Uri Rozovski, Ohad Benjamini, Preetesh Jain, et al.
Leukemia & Lymphoma
|
January 11, 2022
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies
Jan A Burger, Tadeusz Robak, Fatih Demirkan, et al.
American Journal of Hematology
|
August 6, 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
Lorenzo Falchi, Hagop M Kantarjian, Xuemei Wang, et al.
Blood
|
September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Matthew Lunning, Julie Vose, Loretta Nastoupil, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Cancer Immunology Research
|
July 19, 2019
SLAMF6 as a Regulator of Exhausted CD8<sup>+</sup> T Cells in Cancer
Burcu Yigit, Ninghai Wang, Elisa Ten Hacken, et al.
Page
of 23